Supplementary Materials

Supplementary Material for:

Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans

Gissette Reyes-Soffer,* Byoung Moon, Antonio Hernandez-Ono, Marija Dionizovick-Dimanovski, Jhonsua Jimenez, Joseph Obunike, Tiffany Thomas, Colleen Ngai, Nelson Fontanez, Daniel S. Donovan, Wahida Karmally, Stephen Holleran, Rajasekhar Ramakrishnan, Robert S. Mittleman, Henry N. Ginsberg*

*Corresponding author. E-mail: gr2104{at} (G.R.-S.); hng1{at} (H.N.G.)

Published 27 January 2016, Sci. Transl. Med. 8, 323ra12 (2016)
DOI: 10.1126/scitranslmed.aad2195

This PDF file includes:

  • Methods
  • Fig. S1. Study flow diagram.
  • Fig. S2. No changes in LDLR, IDOL, or PCSK9 mRNA levels in HepG2 cells after knockdown of APOB.
  • Fig. S3. ApoB ASO inhibits hepatic secretion of TG and apoB from mice on either chow or HFD diet.
  • Fig. S4. ApoB secretion is increased in Apobec-1 knockout mice on HFD.
  • Fig. S5. ApoB siRNA treatment does not affect expression of Ldlr, Idol, or csk9P in mouse livers.
  • Fig. S6. Hepatic LDL receptor was not affected by ApoB ASO.
  • Fig. S7. Relationship between mipomersen-induced reductions in VLDL apoB PR and baseline VLDL PR.
  • Table S1. Participant information.
  • Table S2. Effect of mipomersen on apoB lipoprotein particle number by ion mobility analysis.
  • Table S3. Effect of mipomersen on apoB lipoprotein size distribution by ion mobility analysis.
  • Table S4. Effect of mipomersen on LDL size subfraction particle numbers by ion mobility analysis.
  • Table S5. Markers of cholesterol synthesis and absorption.
  • Table S6. Hepatic lipase, lipoprotein lipase, FFA, and β-hydroxybutyrate levels.
  • Table S7. Individual participant apoB kinetics of VLDL, IDL, LDL, and VLDL TG FCR.
  • References (4349)

[Download PDF]